SLK Antibody from MYBIOSOURCE INC.
Search, find, compare suppliers for anti-SLK antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | SLK |
| Clone | polyclonal |
| Host Species | Rabbit |
| Reactive Species | human, mouse, rat |
| Isotype | n/a |
| Format | peptide affinity purified |
| Size | 0.1 mL, 0.2 mL |
| Concentration | 1mg/ml |
| Applications | Western Blot (WB), Immunohistochemisty (IHC), Immunofluorescence (IF), Immunocytochemistry (ICC), ELISA (EIA) |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | Specificity: SLK antibody detects endogenous levels of total SLK. Function: Mediates apoptosis and actin stress fiber dissolution.Post-translational Modifications: Proteolytically cleaved by caspase-3. Autophosphorylated.Similarity: Belongs to the protein kinase superfamily. STE Ser/Thr protein kinase family. STE20 subfamily. |
| Immunogen | Immunogen: A synthesized peptide Subcellular Location: Cytoplasmic Tissue Specificity: Ubiquitously expressed. Highest expression is found in heart and in skeletal muscle. Predicted Cross Reactivity: Pig, Bovine, Horse, Sheep, Rabbit, Dog, Chicken, Xenopus Similarity: Pig (100%), Bovine (100%), Horse (100%), Sheep (100%), Rabbit (100%), Dog (100%), Chicken (100%), Xenopus (100%) |
| Other Names | [CTCL tumor antigen se20 9; LOSK; se20 9; Serine/threonine protein kinase 2; SLK; SNF1 sucrose nonfermenting like kinase; STE20 like serine/threonine-protein kinase; STE20 related kinase; STK2] |
| Gene, Accession # | [SLK], Gene ID: 9748, NCBI: NP_001291672.1, UniProt: Q9H2G2 |
| Catalog # | MBS9604892 |
| Price | $240, $280 |
| Order / More Info | SLK Antibody from MYBIOSOURCE INC. |
| Product Specific References | n/a |
MYBIOSOURCE INC.
MYBIOSOURCE INC.
P.O. Box 153308
San Diego CA 92195-3308
P: 1.858.633.0165
P: 1.888.MBS.0165 (1.888.627.0165) (US & Canada)
F: 1.858.633.0166
sales@mybiosource.com
http://www.MyBioSource.com
Profile of MYBIOSOURCE INC.
Return to Antibodies